Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
<p>Abstract</p> <p>Background</p> <p>Ovarian cancer is the most common cause of cancer related death from gynecologic tumors in the United States. The insidious nature of the disease precludes early diagnosis, therefore surgical debulking and chemotherapy are considered...
Main Authors: | Rough James J, Monroy M Alexandra, Yerrum Smitha, Daly John M |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-05-01
|
Series: | Journal of Ovarian Research |
Online Access: | http://www.ovarianresearch.com/content/3/1/13 |
Similar Items
-
Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
by: Jie Ni, et al.
Published: (2018-05-01) -
Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis
by: Dragana Dragoljevic, et al.
Published: (2023-01-01) -
Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy
by: Wei Wang, et al.
Published: (2023-01-01) -
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
by: Kristine Griffett, et al.
Published: (2023-02-01) -
Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis
by: Qian Chen, et al.
Published: (2024-01-01)